Patents by Inventor JENNIFER R. MORGAN

JENNIFER R. MORGAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of spinal cord injury or traumatic brain injury by inhibition of synuclein protein aggregation
    Patent number: 10918657
    Abstract: Methods for the treatment of spinal cord injury or traumatic brain injury are provided. In certain embodiments, the methods include the use of a molecular tweezers and/or nucleobase oligomer capable of inhibiting the accumulation or aggregation of one or more amyloidogenic proteins and/or synuclein proteins. Examples of treatments that may inhibit accumulation or aggregation of one or more amyloidogenic proteins and/or synuclein proteins include treatment with a synuclein antisense nucleobase oligomer or treatment with the molecular tweezers CLR01. These treatments may improve outcomes of spinal cord surgery or traumatic brain injury, including, without limitation, neuronal survival, neuronal regeneration, and recovery of neuronal functions.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: February 16, 2021
    Assignees: The Regents of the University of California, The Marine Biological Laboratory, Board of Regents, The University of Texas System
    Inventors: Jennifer R. Morgan, Gal Bitan, David J. Busch
  • TREATMENT OF SPINAL CORD INJURY OR TRAUMATIC BRAIN INJURY BY INHIBITION OF AMYLOIDOGENIC PROTEINS AND SYNUCLEIN PROTEIN ACCUMULATION OR AGGREGATION
    Publication number: 20150202222
    Abstract: Methods for the treatment of spinal cord injury or traumatic brain injury are provided. In certain embodiments, the methods include the use of a molecular tweezers and/or nucleobase oligomer capable of inhibiting the accumulation or aggregation of one or more amyloidogenic proteins and/or synuclein proteins. Examples of treatments that may inhibit accumulation or aggregation of one or more amyloidogenic proteins and/or synuclein proteins include treatment with a synuclein antisense nucleobase oligomer or treatment with the molecular tweezers CLR01. These treatments may improve outcomes of spinal cord surgery or traumatic brain injury, including, without limitation, neuronal survival, neuronal regeneration, and recovery of neuronal functions.
    Type: Application
    Filed: November 7, 2014
    Publication date: July 23, 2015
    Inventors: JENNIFER R. MORGAN, GAL BITAN, DAVID J. BUSCH